GPT and metabolic dysfunction-associated steatotic liver disease: Indeed, Khan et al. showed that, in addition to the improvement in NAFLD, HFD-fed mice treated with a selective antagonist of peripheral CB1R also had a strong reduction in the biomarkers of liver injury and inflammation associated with NASH, as demonstrated by a significant decrease in circulating transaminases alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH), compared with HFD-fed mice not treated with the CB1R antagonist [60].